Last reviewed · How we verify
NCT05180864: OMEGA-2
Omentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer
NA trial testing Gastrectomy in Stomach Neoplasm in 654 participants. Currently enrolling.
1 January 2029
Quick facts
| Lead sponsor | Amsterdam UMC |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 654 |
| Start date | 1 March 2024 |
| Primary completion | 1 January 2029 |
| Estimated completion | 1 January 2031 |
| Sites | 16 locations across Italy, Netherlands, Germany, United Kingdom |
Drugs / interventions tested
- Gastrectomy
Conditions studied
- Stomach Neoplasm — all drugs for Stomach Neoplasm →
Sponsor
Amsterdam UMC — full company profile →
Who can join
18 and older, any sex, with Stomach Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Curative therapy for gastric cancer usually consists of perioperative chemotherapy and a radical (R0) gastrectomy. A radical resection includes a modified D2 lymphadenectomy, and, generally, a complete omentectomy, to ensure the removal of omental metastatic lymph nodes and tumor deposits. The omentum has some essential functions within the peritoneal cavity. The omentum functions as regulator of regional immune responses to prevent infections and, additionally, it prevents adhesions that can lead to small bowel obstruction. Omentectomy is associated with increased incidence of early and late postoperative complications such as abdominal abscess, ileus, and wound infections in various types of surgery. There is little evidence regarding survival benefit of routine complete omentectomy during gastrectomy. The investigators hypothesize that omitting a complete omentectomy (and instead preserve the greater omentum distal of the gastroepiploic arcade) during gastrectomy for cancer does not negatively impact survival. OMEGA is a randomized controlled, open, parallel, non-inferiority, multicenter trial. Adult patients (\>18 years) with primary resectable gastric cancer, clinical stage T2-4a N0-3 M0 or cT1N+ scheduled for open or minimally invasive (sub)total gastrectomy are included. The primary study objective is to investigate whether omentum preservation in gastrectomy for cancer is non-inferior to complete omentectomy in terms of three-year overall survival.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Omentum preservation versus complete omentectomy in gastrectomy for gastric cancer (OMEGA trial): study protocol for a randomized controlled trial.
Keywani K, Eshuis WJ, Borgstein ABJ, van Det MJ, et al · · 2024 · cited 1× · PMID 39232781 · DOI 10.1186/s13063-024-08396-z
Verify or expand the search:
- PubMed search for NCT05180864
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Gastrectomy
Trials testing the same drug.
- NCT05038098 — Magnetic Sentinel Lymph Node Mapping in Gastric Cancer · Phase 1 · not yet recruiting
- NCT06798376 — Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer · recruiting
- NCT05800236 — Characterisation of the Intratumoral Microbiome in Gastric Adenocarcinoma: to a Personalised Medicine · NA · unknown
- NCT05753306 — Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Periton · Phase 2 · recruiting
- NCT05604378 — Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric Carcinogenesis · completed
Other recruiting trials for Stomach Neoplasm
Currently open trials in the same condition.
- NCT06732856 — A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locall · Phase 1, PHASE2 · recruiting
- NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
- NCT06923449 — Gastric Cancer' Textbook Oncological Outcome and Tumor Board Performance · recruiting
- NCT05640609 — Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer · Phase 1, PHASE2 · recruiting
- NCT05698992 — Rehabilitation and Recovery for Persons with Esophageal or Gastric Cancer · recruiting
Other Amsterdam UMC trials
Trials by the same sponsor.
- NCT06962072 — Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma · recruiting
- NCT06493591 — Atrial Fibrillation Ablation and Autonomic Modulation Via Thoracoscopic Surgery, 10 Year Follow up. · not yet recruiting
- NCT06399731 — Non-invasive Brain Stimulation for the Treatment of Mild Cognitive Impairment in Parkinson's Disease · NA · recruiting
- NCT03222635 — Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05180864 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amsterdam UMC
- Last refreshed: 4 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05180864.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing